Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 4. Effect of the FDA-approved drugs on the replication of SARS-CoV-2 and cell viability. (A-C) Vero E6 cells were infected with a 0.1 MOI of SARS-CoV-2 in 6-well plates and then treated with 0.1% DMSO, atovaquone (A), abiraterone acetate (B) or digoxin (C) in a dose-dependent manner at 3 h after virus infection. Supernatants of the virus-infected cell cultures were collected at 48 h after virus infection. Viral replication was quantified by plaque formation assay. *p<0.05, **p<0.01. (D) Effect of the FDA-approved drugs on the cell viability of Vero E6 cells. Vero E6 cells were cultured in DMEM medium containing 2% FBS with the indicated concentrations of each FDA-approved drug for 48 h. The cells were incubated with CCK-8 solution, and then, soluble formazan was measured using a microplate reader.
Biomolecules & Therapeutics 2022;30:427~434
© Biomolecules & Therapeutics